These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1037636)

  • 1. Leukocyte migration inhibition in vitro in untreated and methimazole-treated patients with Graves disease.
    Kálmán K; Fazakas S; Erdei I; Leövey A
    Acta Med Acad Sci Hung; 1976; 33(4):327-32. PubMed ID: 1037636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte migration test for the study of immune reactivity in cases of Graves disease associated with infiltrative ophthalmopathy.
    Kálmán K; Erdei I; Sándor P; Fazakas S; Leövey A
    Acta Med Acad Sci Hung; 1978; 35(1):29-34. PubMed ID: 581631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
    Karlsson FA; Tötterman TH
    Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
    Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
    Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of cellular immunity in Graves' disease.
    Zosin I; Simionescu L; Arcan P; Lungu G
    Endocrinologie; 1983; 21(4):267-72. PubMed ID: 6364320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No prognostic value of thyroid autoantibodies changes during and after methimazole therapy in patients with Graves' disease.
    Lattanzi V; Ciampolillo A; Vincenti C; Giorgino R
    Boll Soc Ital Biol Sper; 1985 Apr; 61(4):507-13. PubMed ID: 3840026
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunological monitoring in lung cancer: use of the leukocyte migration inhibition assay.
    Abai AM; Fekete B
    Haematologia (Budap); 1982; 15(1):111-25. PubMed ID: 6749608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J; Gao H; Xu L
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of glucose and glutamine in lymphocytes from Graves' hyperthyroid patients: influence of methimazole treatment.
    Werner MC; Costa Rosa LF; Romaldini JH; Curi R
    Cell Biochem Funct; 1996 Jun; 14(2):97-104. PubMed ID: 8640958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-mediated immunity against digestive organ cancers : leucocyte migration inhibitory factor activity as an immunological parameter.
    Hamasaki K
    Acta Med Okayama; 1977 Jun; 31(3):147-59. PubMed ID: 144415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithyroid drug-induced immunomodulation in Graves' disease patients.
    Lechpammer M; Lukac J; Lechpammer S; Kusić Z
    Acta Med Croatica; 2002; 56(1):21-6. PubMed ID: 12455450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-dependent cell-mediated cytotoxicity in Graves disease.
    Balázs C; Leövey A; Szerze P; Kovács L; Bordán L
    Acta Med Acad Sci Hung; 1977; 34(4):235-9. PubMed ID: 581819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spiking expression of mu-crystallin mRNA during treatment with methimazole in patients with graves' hyperthyroidism.
    Suzuki S; Takei M; Nishio S; Inaba H; Sato A; Yamazaki M; Shinomiya K; Hashizume K
    Horm Metab Res; 2009 Jul; 41(7):548-53. PubMed ID: 19280551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition of leukocyte migration induced by sera of patients with Basedow's disease of autimmune diseases].
    Puppo F; Di Benedetto G; Barabino A; Soldà AM; Priolo C; Indiveri F
    Boll Soc Ital Biol Sper; 1977 Apr; 53(7):531-7. PubMed ID: 578774
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of leukocyte migration by tumor-associated antigen in soluble extracts of human hepatoma.
    Lee C; Chen S; Lin T
    Cancer Res; 1977 Mar; 37(3):918-21. PubMed ID: 189919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.